Study summary · research use only
Provisional Treatment of Volumetric Muscle Loss With Insulin-like Growth Factor 1 Releasing Muscle Void Fillers
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
In this study, adult male Lewis rats underwent volumetric muscle loss (VML) surgery followed by implantation of a polyethylene glycol-acrylate muscle void filler (MVF) containing soluble or PLGA-encapsulated insulin-like growth factor 1 long arginine 3 (IGF1-LR3) at a low (28 μg) or high (280 μg) dose, or no IGF1-LR3 (control), with neuromuscular function assessed by isometric torque and tissue analyzed by staining. High-dose PLGA-encapsulated IGF1-LR3 was associated with increased muscle weight versus control at 28 days post-implantation, but no differences were observed between groups in specific or maximum torque, muscle fibrosis, or fiber size or count. The authors state that IGF1-LR3 in this MVF did not enhance neuromuscular function or muscle fiber hypertrophy in this model.
Abstract
Volumetric muscle loss (VML) resulting from severe extremity injuries in combat remains a significant clinical challenge, particularly in austere environments. Current research emphasizes the development and evaluation of definitive treatments, largely neglecting acute stabilization strategies. To address this unmet need, this study investigated the efficacy of delivering insulin-like growth factor 1 long arginine 3 (IGF1-LR3) via a synthetic in situ forming hydrogel muscle void filler (MVF) to enhance muscle recovery after VML. Adult male Lewis rats underwent VML surgery, followed by implantation of a polyethylene glycol-acrylate MVF containing either soluble or poly(lactic-co-glycolic acid) (PLGA)-encapsulated IGF1-LR3 at a low (28 μg) or high (280 μg) dose, or no IGF1-LR3 (control). Neuromuscular function was assessed via isometric torque measurements. Muscle tissue was analyzed using wheat germ agglutinin and picrosirius red staining for fiber size, count, and fibrosis. Statistical analysis was performed using ANOVA with Holm-Šídák post hoc testing. High-dose PLGA-encapsulated IGF1-LR3 resulted in increased muscle weight compared to the control group at 28 d post implantation. However, no differences were observed in specific torque or maximum torque production between any experimental groups. Histological analysis revealed no changes in muscle fibrosis or fiber size or count of IGF1-LR3 compared to controls. The addition of IGF1-LR3 in an MVF did not enhance neuromuscular function or muscle fiber hypertrophy. Further studies are needed to optimize IGF1-LR3 delivery or alternative hypertrophy-inducing soluble factors.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.